Jenburkt Pharmaceuticals zooms on planning to launch Favipiravir-200 mg tablets

21 Jul 2020 Evaluate
Jenburkt Pharmaceuticals is currently trading at Rs. 445.00, up by 47.45 points or 11.94% from its previous closing of Rs. 397.55 on the BSE.

The scrip opened at Rs. 397.55 and has touched a high and low of Rs. 469.95 and Rs. 387.00 respectively. So far 22143 shares were traded on the counter.

The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 559.00 on 25-Jul-2019 and a 52 week low of Rs. 243.20 on 19-Mar-2020.

Last one week high and low of the scrip stood at Rs. 469.95 and Rs. 380.00 respectively. The current market cap of the company is Rs. 181.26 crore.

The promoters holding in the company stood at 45.73%, while Institutions and Non-Institutions held 2.22% and 52.05% respectively.

Jenburkt Pharmaceuticals has planned to launch Favipiravir-200 mg tablets, recommended for the treatment of mild to moderate COVID-19 patients.

Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.

Jenburkt Pharma Share Price

846.00 6.05 (0.72%)
14-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.